AASLD 2025 7 - 10 November 2025

SomaSignal defined MASH disease components are prognostic of secondary cardiovascular disease – A post-hoc analysis of the SELECT trial

Authors :

Arun J. Sanyal¹; Steen Ladelund²; Michelle T. Long²; Sune Boris Nygård²; Adel Belloum²; Jörn M. Schattenberg³

Affiliations

View Details Hide Details

{{ getPageNum(PDFPage) }}

Download poster (.pdf)

Keywords

MASH

Congress poster

GLP-1 RA

Semaglutide

PHASE 3 (RCT)